stem cells

FDA Halts Plan for Vertex, CRISPR Therapeutics Sickle Cell Study
FDA Halts Plan for Vertex, CRISPR Therapeutics Sickle Cell Study
Xconomy
sickle cell disease
FDA
Vertex Pharmaceuticals
CRISPR Therapeutics
CTX001
stem cells
Flag link:
Novo Nordisk steps up interest in diabetes, Parkinson’s stem cell therapies
Novo Nordisk steps up interest in diabetes, Parkinson’s stem cell therapies
Fierce Biotech
Novo Nordisk
type 1 diabetes
stem cells
Flag link:
Citing significant progress on a cure for diabetes, Novo Nordisk beefs up its stem cell pipeline with new collaborations
Citing significant progress on a cure for diabetes, Novo Nordisk beefs up its stem cell pipeline with new collaborations
Endpoints
Novo Nordisk
type 1 diabetes
stem cells
Biolamina
Flag link:
Cellular Biomedicine Group to Release 48-week Data from Phase I Clinical Trial for Promising Stem Cell Therapy AlloJoin for Knee Osteoarthritis
Cellular Biomedicine Group to Release 48-week Data from Phase I Clinical Trial for Promising Stem Cell Therapy AlloJoin for Knee Osteoarthritis
CP Wire
Cellular Biomedicine
Allojoin
stem cells
osteoarthritis of the knee
Flag link:
Amgen bets on stem cell company Fortuna Fix in $25M round
Amgen bets on stem cell company Fortuna Fix in $25M round
Endpoints
Amgen
stem cells
Fortuna Fix
Flag link:
A Change in Direction on Stem Cell Policy? It’s About Time
A Change in Direction on Stem Cell Policy? It’s About Time
FDA Law Blog
FDA
stem cells
Flag link:
CSL snags a preclinical stem cell therapy in $416M Calimmune buyout
CSL snags a preclinical stem cell therapy in $416M Calimmune buyout
Endpoints
CSL
Calimmune
M&A
stem cells
Flag link:
J&J turns its back on Capricor and its failed stem cell tech, taking its money and rep with it
J&J turns its back on Capricor and its failed stem cell tech, taking its money and rep with it
Endpoints
JNJ
Capricor
stem cells
Linda Marban
Flag link:
New Texas Law on Stem Cell Treatments: Showdown With FDA Coming?
New Texas Law on Stem Cell Treatments: Showdown With FDA Coming?
RAPS.org
Texas
FDA
stem cells
Flag link:
Athersys And Aurinia Target Human And Animal Health
Athersys And Aurinia Target Human And Animal Health
Seeking Alpha
Athersys
Aurinia Pharmaceuticals
animal health
stem cells
Flag link:
Texas on track to become first state to explicitly back stem cell therapies
Texas on track to become first state to explicitly back stem cell therapies
Stat
Texas
stem cells
Flag link:
Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it
Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it
Endpoints
Magenta Therapeutics
Novartis
stem cells
HSC835
Flag link:
How AbbVie Is Attacking Tumors at Their Roots
How AbbVie Is Attacking Tumors at Their Roots
Motley Fool
AbbVie
solid tumors
cancer
stem cells
Stemcentrx
Rova-T
Flag link:
Three patients blinded by stem cell procedure, physicians say
Three patients blinded by stem cell procedure, physicians say
Stat
US Stem Cell
stem cells
clinical trials
macular degeneration
Flag link:
9 cardiology breakthroughs you need to know
9 cardiology breakthroughs you need to know
Mass Device
cardiology
Prevencio
Medtronic
3D printing
robotic heart sleeve
devices
aortic stenosis
stem cells
pacemakers
Flag link:
Takeda, TiGenix stem cell therapy shows sustained effect
Takeda, TiGenix stem cell therapy shows sustained effect
Fierce Biotech
Takeda
TiGenix
stem cells
Cx601
Crohn's Disease
Flag link:
Orthocell, J&J’s DePuy Synthes ink R&D deal for stem cell treatment
Orthocell, J&J’s DePuy Synthes ink R&D deal for stem cell treatment
Mass Device
Orthocell
JNJ
DePuy Synthes
R&D
stem cells
devices
Flag link:
STAT’s stats of the year: 2016 by the numbers
STAT’s stats of the year: 2016 by the numbers
Stat
Pharma
biotech
drug ads
stem cells
CRISPR
Medicare
Zika virus
venture capital
Flag link:
Once-promising diabetes ‘breakthrough’ comes unglued with a major retraction
Once-promising diabetes ‘breakthrough’ comes unglued with a major retraction
Stat
diabetes
stem cells
Regeneron
Flag link:
Bayer, Versant close $225m Series A to launch stem cell company
Bayer, Versant close $225m Series A to launch stem cell company
Mass Device
Bayer
Versant Ventures
stem cells
Series A
BlueRock Therapeutics
devices
regenerative medicine
Flag link:

Pages